Liver and COVID-19 - A Review and Clinical Approach

Fisher, D. L.; Malnick, S.

Fisher, D. L.; Malnick, S..

Coronaviruses ; 3(1):49-55, 2022.

Article in English | EMBASE | ID: covidwho-2259259

ABSTRACT

ABSTRACT

Liver enzyme abnormalities occur frequently in patients diagnosed with Coronavirus disease 2019 (COVID-19). It has been suggested that patients with severe acute liver injury are more likely to be admitted to intensive care, require intubation or renal replacement therapy and their mortality rate is higher than patients without severe acute liver injury. This review article explores the possible aetiologies of liver dysfunction seen in patients with COVID-19 and also the effect of COVID-19 on patients with pre-existing liver disease. Finally, we suggest clinical approaches to treating a patient with liver enzyme disturbance and COVID-19 and also caring for patients who require liver transplantation in the COVID-19 era.Copyright © 2022 Bentham Science Publishers.

Keywords

coronavirus disease 2019, covid-19, hepatitis, liver disease, liver transplant, mafld, alanine aminotransferase blood level, alcohol liver disease, aspartate aminotransferase blood level, autoimmune hepatitis, chronic hepatitis B/ep [Epidemiology], chronic hepatitis B/su [Surgery], chronic hepatitis C/ep [Epidemiology], chronic liver disease/ep [Epidemiology], computer assisted tomography, convalescent plasma therapy, coronavirus disease 2019/dt [Drug Therapy], coronavirus disease 2019/pc [Prevention], coronavirus disease 2019/th [Therapy], disease exacerbation, drug efficacy, gamma glutamyl transferase blood level, human, immunosuppressive treatment, infection risk, intensive care, intubation, liver cell carcinoma, liver cirrhosis, liver dysfunction/di [Diagnosis], liver dysfunction/ep [Epidemiology], liver dysfunction/si [Side Effect], liver function test, liver injury/et [Etiology], liver transplantation, low drug dose, metabolic fatty liver/di [Diagnosis], metabolic fatty liver/ep [Epidemiology], mortality rate, nonalcoholic fatty liver, prevalence, renal replacement therapy, review, risk factor, side effect/si [Side Effect], steroid therapy, alanine aminotransferase/ec [Endogenous Compound], antivirus agent, aspartate aminotransferase/ec [Endogenous Compound], azathioprine, danoprevir/cb [Drug Combination], danoprevir/dt [Drug Therapy], dexamethasone/dt [Drug Therapy], gamma glutamyltransferase/ec [Endogenous Compound], ledipasvir/dt [Drug Therapy], ledipasvir plus sofosbuvir/dt [Drug Therapy], liver enzyme/ec [Endogenous Compound], lopinavir plus ritonavir/ae [Adverse Drug Reaction], lopinavir plus ritonavir/dt [Drug Therapy], mycophenolic acid, nucleoside analog, remdesivir/ae [Adverse Drug Reaction], remdesivir/dt [Drug Therapy], ritonavir/cb [Drug Combination], ritonavir/dt [Drug Therapy], sofosbuvir plus velpatasvir/dt [Drug Therapy], velpatasvir/dt [Drug Therapy]

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study Language: English Journal: Coronaviruses Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google